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Background: Conformal intensity-modulated radiation therapy (IMRT) involves irradiation of large volume of normal
tissue with low and medium doses, biological relevance of which is not clear yet. Serum proteome features were
used here to study the dose-volume effects in patients irradiated with IMRT due to head and neck cancer.
Methods: Blood samples were collected before and during RT, and also about one month and one year after the
end of RT in a group of 72 patients who received definitive treatment. Serum proteome profiles were analyzed
using MALDI-ToF mass spectrometry in 800–14,000 Da range.
Results: Major changes in serum proteome profiles were observed between pre-treatment samples and samples
collected one month after RT. Radiation-related changes in serum proteome features were affected by low-to-medium
doses delivered to a large fraction of body mass. Proteome changes were associated with intensity of acute
radiation toxicity, indicating collectively that RT-related features of serum proteome reflected general response of
patient’s organism to irradiation. However, short-term dose-related changes in serum proteome features were not
associated significantly with the long-term efficacy of the treatment.
Conclusions: The effects of low and medium doses of radiation have been documented at the level of serum
proteome, which is a reflection of the patient’s whole body response.
Keywords: Dose effects, Head and neck cancer, IMRT, Radiation toxicity, Serum proteomeBackground
Radiotherapy (RT), either alone or in combination with
chemotherapy, is an effective treatment of different types
of cancer, including head and neck squamous cell carcin-
oma, which allows preserving the structure and function
of a target organ. Successful RT of patients with advanced
cancer usually requires aggressive methods of treatment,
which include accelerated fractionation successfully im-
plemented in radical treatment of head and neck cancer
[1,2]. However, application of such a treatment increases* Correspondence: widlak@io.gliwice.pl
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reproduction in any medium, provided the orrisk of unacceptable toxicity to normal tissue, where radi-
ation induces damage leading to acute and/or late injury
reactions [3].
Differences in repair of radiation damage between
tumor and normal tissue are the main biological concept
of radiotherapy, and until the end of 20th century radi-
ation therapy was applied using two opposite radiation
fields with similar doses delivered to tumor and normal
tissue (dose fractionation was used to reduce toxicity of
such a treatment). In recent two decades development
of advanced 3D radiation treatment planning systems
and technological progress in construction of linear
accelerators with multileaf collimators (MLC) allowed
on real differentiation of radiation doses between tumorLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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radiotherapy is based on the focusing of several radiation
fields in the target volume, allowing a higher dose of ra-
diation to be delivered to the tumor and (intentionally)
reducing its toxicity to the surrounding normal tissues.
The intensity-modulated radiation therapy (IMRT) is the
next step in optimization of radiation dose. This technique
takes advantage of treatment planning systems by calculat-
ing the optimal position of MLC during irradiation, which
results in better differentiation of dose between normal
tissue and tumor [4]. Introduction of many non-coplanar
radiation fields results in irradiation of larger volumes of
normal tissues with small doses of radiation comparing to
two-field technique, yet the increase in volume of patient’s
body exposed to low doses of radiation is a potential draw-
back of IMRT. Theoretically irradiation with small doses
should not introduce substantial damage to normal tissues
because of a threshold in the dose-effect relationship. On
the other hand, however, the whole body effect of irradi-
ation using IMRT has not been studied in depth because
of the lack of existing end-points and biological markers
of irradiation to small doses. In fact, the only concern re-
garding IMRT that has been examined so far is a treat-
ment of children in the context of a risk of secondary
cancers. Hence, documenting the possible biological ef-
fects of irradiation of large masses of normal tissues with
low and medium doses is an urgent issue rev. in: [5,6].
The low-molecular-weight fraction of serum/plasma
proteome (up to 15,000 Da) appears to be a promising
source of novel biomarkers rev. in: [7,8]. Several published
studies on mass spectrometry-based profiling of this frac-
tion of blood have revealed multi-peptide signatures that
could be used for detection and/or classification of cancer.
Noteworthy, several components of proposed cancer
signatures, especially those characteristic for advanced
cancer, were identified as fragments of blood proteins
involved in general response of patient’s organism to the
disease. Of note, profiling of serum/plasma proteome
revealed features that reflected general reaction of the pa-
tient’s whole body to anticancer treatment [8-10]. A few
published works used this approach aiming to detect
radiation-related effects in locally irradiated cancer pa-
tients. These works reported changes in serum proteome
profiles between pre-exposure and post-exposure samples,
and found differences between samples from patients ex-
posed to different doses of radiation [11,12]. Although
both reports documented the influence of radiation doses
on therapy-related changes in the serum proteome, they
focused on the radiation doses delivered to tumor volume.
Here, we hypothesized that the whole body response of a
patient to the treatment may be related not only to high
doses delivered to tumor volume but also to low- and
medium-doses delivered during IMRT to large volume of
normal tissue.Methods
Characteristics of patient group
Seventy two patients with head and neck squamous cell
cancer were enrolled into this prospective study; all partic-
ipants were Caucasians (51 men), 40–80 years old (median
age 60 years), mostly current smokers (85%) and alcohol
consumers (83%). Cancer was located at either oropharynx
(31), hypopharynx (8) or larynx (33); primary tumor stage
was scored as: T1 (7%), T2 (43%), T3 (34%) and T4 (16%);
51% of N0. All patients were subjected to IMRT using 6
MeV photons (1.8 Gy daily fraction doses according to the
continuous accelerated irradiation scheme, CAIR [2]).
Total radiation doses delivered to gross tumor volume
(GTV) were in the 66.6-73.8 Gy range (median 72 Gy),
overall treatment time was between 38–49 days (median
41 days). Neither surgery nor induction/concomitant
chemotherapy was applied to patients enrolled in the
study. The acute mucosal reaction (AMR) was assessed
using the Dische score system [13,14] each 3–5 days
during the RT. Three-year recurrence-free survival was
observed in 36 patients, while treatment failure due to
local recurrence, distant metastases and/or second tumor
was noted in 25 patients during the same follow-up. Four
consecutive blood samples (5 ml) were collected from
each patient: pre-treatment sample A (within one week
before RT; 72 patients); within-treatment sample B (9–23
days after the start of RT; median 15 days; 72 patients);
post-treatment sample C (16–73 days after the end of RT;
median 34 days; 68 patients) and post-treatment sample D
(52–714 days after the end of RT; median 460 days, 59 pa-
tients). The study was approved by local Ethics Committee
at the Cancer Center in Gliwice and all participants pro-
vided informed consent indicating their conscious and
voluntary participation.
Irradiated volumes and related radiation doses were
read from treatment plans that based on CT scans of
head, neck and upper thorax region (using the ECLIPSE
radiation therapy planning system). Because the CT scans
always include region containing all radiation fields assess-
ment of doses and volumes is straightforward. The dose-
volume histograms (DVH, see below) represent volume of
irradiated tissue irradiated with specific dose level (accord-
ing to the treatment plans), which is an important element
of evaluation of IMRT plan.
Sample preparation and serum mass profile acquisition
Collected blood was incubated for 30 min. at room
temperature to allow clotting, and then centrifuged at
1000 g for 10 min. to remove the clot. The serum was
aliquoted and stored at −70°C. Directly before analysis
samples were diluted 1:5 with mixture of acetonitrile
(20%) and ammonium bicarbonate (250 mM), and then
albumin and other large-molecular-weight proteins were
removed by centrifugation (30 minutes, 3000 g) through
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(Millipore). Each sample was loaded onto a C18 ZipTip
micro-column by passing it through repeatedly 15 times
until saturation, then column was washed with water
and eluted with 1 μl of matrix solution (saturated solu-
tion of alpha-cyano-4-hydroxycinnamic acid in 50%
ACN/H2O and 0.1% TFA) directly onto the 600 μm
AnchorChip (Bruker Daltonics) plate. Samples were ana-
lyzed using an Ultraflextreme MALDI-ToF spectrometer
(Bruker Daltonics, Bremen, Germany); the analyzer worked
in the linear mode and positive ions were recorded in the
mass range between 800 and 14,000 Da. ZipTip extraction/
loading was repeated twice for each sample and for each
spot two averaged spectra were recorded (i.e. four spectra
were acquired for each sample). All samples were analyzed
in a random sequence to avoid a possible batch effect.
Analysis of mass profiles
The pre-processing of spectra, which included baseline
removal, alignment and averaging of technical repeats,
and normalization of the total ion current (TIC), was
performed according to procedures considering to be
standard in the field [15]. In the second step the spectral
components, which reflected [M+H]+ peptide ions re-
corded at defined m/z values, were identified using
decomposition of mass spectra into their Gaussian com-
ponents followed by several post-processing steps as de-
scribed in more details elsewhere [16,17]. The average
spectrum was decomposed into a sum of Gaussian bell-
shaped curves by using a variant of the expectation
maximization (EM) algorithm and Bayesian Information
Criterion (BIC) for model selection [18]. The initial set
of 366 Gaussian components, defined by their mean values
and standard deviations, was further processed to merge
overlapping components (components homogenous in
variance and with main values closer than 0.1% of the m/z
value) and to remove components presumably represent-
ing the residual baseline (components with coefficient of
variation bigger than 25%), which resulted in dimension
reduction to 319 Gaussian components. The final 319
Gaussian components were used to compute features of
registered spectra (termed spectral components afterward)
for all samples by the operations of convolutions with
Gaussian masks. The knowledge base EPO-KB (Empirical
Proteomic Ontology Knowledge Base) [19], which links
m/z values to known peptide/proteins, was used for hypo-
thetical annotation of spectral components.
Statistical analyses
For each serum component the normality of distribution
of changes was assessed using the Lilliefors test to provide
optimal tools for statistical analysis. Either the t-test or the
Wilcoxon test corrected for multiple testing with false
discovery rate (FDR) estimation was applied for analyzingchanges in abundances of spectral components. Correl-
ation between abundance of spectral components and pa-
rameters reflecting absorbed doses of radiation was
analyzed using either the Pearson’s correlation coefficient
or the Spearman’s rank correlation coefficient (depending
on the type of distribution). Total radiation energy
absorbed by patient’s body was estimated from the individ-
ual DVH generated during the treatment planning by cal-
culating its integral over dose. For the analysis of dose/
volume effect doses corresponding to deciles of the area
under curve of the averaged DVH were selected (see
below) Correlation between maximal intensity of the
AMR and abundance of spectral components or radiation
doses was analyzed using the Spearman’s rank correlation
coefficient.
Results
Exposure to ionizing radiation resulted in gross changes
of the low-molecular-weight component of serum
proteome
A typical MALDI-ToF mass spectrum registered in the
800–14,000 Da range (319 spectral components or pep-
tide ions were distinguished in this range) and a differ-
ential spectrum obtained for two consecutive samples is
exemplified on Figure 1A. Pairwise differential spectra
were computed for consecutive samples collected from
each donor, and then the statistical significance of differ-
ences in peptide abundances was estimated. Numbers of
spectral components that changed their abundances be-
tween compared time points are presented in Figure 1B
(detailed data are presented in Additional file 1: Table S1).
The B samples represented the first weeks of radiotherapy
after accumulation of about 1/3 of total dose when the
first signs of radiation toxicity were visible. The C samples
reflected early effects of the completed treatment when
total radiation dose was delivered and healing of radiation
mucositis was observed. The D samples reflected longer
follow-up where early radiation effects were completely
healed and late effects of RT on both normal mucosa and
tumor (cancer eradication or ongoing recurrence) might
be detected. Several serum components (~8% of detected
peptide ions) changed their abundance at a high level of
statistical significance (FDR < 0.1%) during the first two
weeks of radiotherapy (the AΔB change). However, the
major changes were observed when post-treatment serum
samples C were analyzed. About 45% of detected peptide
ions changed their abundance significantly (FDR < 0.1%)
between samples A and C, while about 24% of peptide
ions changed their abundance between samples B and C.
A substantial part of changes observed during the first
two weeks of RT deepen until sample C, however, majority
of changes (~70%) observed one month after the end of
RT (sample C) were not detected earlier after the first two
weeks of RT. Changes observed during a longer follow-up
Figure 2 Radiotherapy-related changes in patterns of serum
proteome features. Panel A – The numbers of spectral
components that followed particular patterns of changes between
analyzed time points (either decrease and increase marked with
corresponding arrows, or lack of statistically significant differences).
Panel B – Examples of registered peptide ions that represented four
specific patterns of changes; boxplots show: minimum, lower
quartile, median, upper quartile and maximum values.
Figure 1 Radiation-induced changes in serum proteome
profiles. Panel A - Typical mass spectrum of the serum proteome in
the 800–14,000 Da range and differential spectrum computed for
samples collected before and during radiotherapy. Panel B - Numbers
of spectral components that changed their abundances between
consecutive samples at high level of statistical significance (FDR < 5%
or FDR < 0.1%, the latter ones in brackets).
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concluded that exposure to ionizing radiation resulted in
gross changes detected primarily early after the end of the
treatment. Importantly, the treatment-related changes
could be detected several months after the end of treat-
ment, hence abundances of about 18% of detected peptide
ions were still significantly different (FDR < 0.1%) when
samples collected before the treatment (sample A) and
more than one year after the end of RT (sample D) were
compared. Of note, we did not observe a statistically
significant association of RT-induced changes of serum
proteome features with cancer stage or location.
Radiation-induced changes in the serum proteome
profiles could be reversed during long time follow-up
We analyzed kinetics of radiotherapy-related changes in
serum proteome patterns during the longer follow-up.
Diagram in Figure 2A shows the numbers of peptide
ions that changed their abundance following specific
patterns; “early” changes detected between samples A
and C, and “late” changes detected between samples C
and D were analyzed (p = 0.05 was selected as a signifi-
cance threshold for increased or decreased abundance).We observed that substantially more serum components
decreased in their abundances between samples A and C
(238 out of 319) than increased in their abundances
between these samples (27 out of 319). Interestingly,
“early” changes detected during short time after the
treatment (the AΔC change) appeared to be somehow
reversed/compensated by “late” changes observed during
longer follow-up (the CΔD change). Such “reversing”
effect was much more frequent than “deepening” of
changes: 60 vs. 20 and 9 vs. 1 components that either
decreased or increased their abundance during the
“early” phase, respectively; only in case of a few serum
components changes induced during the treatment (or
short time after the end of RT) were deepen during
longer follow-up. Figure 2B shows examples of peptide
ions representing different patterns of changes observed
during the treatment and its follow-up (with “late”
changes that either reverse or deepen “early” changes);
namely abundances of components with m/z 1504 Da,
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changes in serum proteome profiles suggest that RT-
induced effects are related mostly to accumulation
and healing of early radiation effects (e.g. radiation
mucositis).
Treatment-related changes in serum proteome profiles
were associated with volumes of irradiated tissues and
doses of radiation received by patients
In the second step of the study we searched for association
between features of serum proteome profiles and doses of
ionizing radiation received by patients (doses accumulated
until a time point corresponding to the collection of sam-
ple B in case of the AΔB changes and total doses in case
of the AΔC, BΔC and CΔD changes). Correlations were
identified between specific changes in abundances of the
detected peptide ions (i.e., features of serum proteome)
and either the total (maximum) dose received by the gross
tumor volume (GTV), volume of the patient’s body irradi-
ated at different (smaller) doses or total radiation energy
absorbed by patient’s body. The total doses are regarded
as maximum tolerated doses, and are delivered to tumor
and its adjacent margins (usually 100–200 ccm). Total ra-
diation energy absorbed by patient’s body was estimated
from the individual DVH by calculating its integral over
dose (radiation dose multiplied by mass approximated
from volume of irradiated tissue reflected absorbed en-
ergy); such energy was usually up to 300 J. Table 1 shows
the numbers of serum components, which changes in
abundances correlated with either maximum GTV dose
or total absorbed radiation energy; p = 0.05 was selected
as a statistical significance threshold. We found that
changes in abundances of several serum components
correlated with both maximum doses delivered to the
target tumor volume and total radiation energy absorbed
by whole patient’s body, and could be detected for both
“early” changes (during and soon after the treatment) as
well as “late” changes (during long-term follow-up). In
general, more serum features correlated with the totalTable 1 Numbers of serum components correlated with
GTV doses, total absorbed radiation energy (TARE) and
maximum AMR intensity





AΔB 4 26 19 4894, 6282 [CYTC], 9715
BΔC 13 29 11 1192, 1209, 1266 [A4]
AΔC 4 5 11 5194, 5215
CΔD 13 17 10 2110 [A4], 2994
AΔD 4 32 10 1334 [FIBA], 1433, 5407 [S10A8]
Presented are examples of components showing significant correlation with
both AMR and radiation doses; p = 0.05 was selected as a significance
threshold level.radiation energy absorbed by the whole patient’s body
(that in large part reflected doses delivered to normal tis-
sue) than with the maximum GTV dose. Hence, effects re-
lated to a high dose of radiation received by a small
volume of tumor and adjacent tissue (about 70 Gy in this
case), and clinically/therapeutically low-to-medium doses
received by a large volume of normal tissue were com-
pared. Due to the characteristics of IMRT, tissue irradiated
with lower doses represent much higher volumes (e.g.
about 4,000 ccm irradiated with 10 Gy; see Figure 3A).
Detailed data on correlation of serum proteome features
with volumes irradiated at a given dose or with doses
delivered to a given volume are presented in Additional
file 1: Tables S2-S6. We found that “low- and medium-
dose effects” were more frequent than “high-dose ef-
fects” when RT-induced serum proteome changes were
analyzed (Figure 3B). Medium-dose effects were ob-
served when the first phase of the treatment was ana-
lyzed (the AΔB changes); the highest number of serum
features correlated with the volume of tissues irradiated
at about 1 Gy dose fractions. However, low-dose effects
predominated when the second phase of the treatment
was analyzed (the BΔC changes); the highest number of
serum features correlated with the volume of tissues
irradiated at 0.16-0.33 Gy dose fractions (cumulated
dose 6.8 or 13.7 Gy). Similar effects of low doses were
observed when the “late” CΔD changes or the “overall”
AΔD changes were analyzed. In all cases a relatively low
number of serum features correlated with the volume of
tissues irradiated at high doses (i.e. 1.5-1.8 Gy dose frac-
tions). The same results were obtained when reverse
analysis was performed - serum proteome features were
correlated with a dose delivered to a given volume
(Additional file 1: Tables S2-S6). All these observations
indicated coherently that changes observed in the serum
proteome patterns during and early after RT were primar-
ily affected by low-to-medium doses of radiation absorbed
by large fractions of patient’s body mass.
Changes in serum proteome profiles were associated with
toxicity of the treatment
Aiming to examine presumable association of serum
proteome with radiation toxicity we searched for correl-
ation between dose-related changes in serum proteome
features and clinical response to the treatment. The in-
tensity of the acute mucosal reaction (AMR), which is a
clinically relevant response of normal tissues to early
toxicity of radiation [3] was assessed using a modified
Dische system [13,14]. First, we have established correl-
ation between the maximum AMR intensity and absorbed
radiation doses. The maximum AMR intensity varied indi-
vidually and was usually observed 20-40 days after the
start of RT, yet linear increase of all irradiation parameters
justified establishing correlation between the AMR and
Figure 4 Dose-effect in radiation response. Panel A – Correlation
between the maximum AMR intensity and volume of tissue
irradiated a given dose; bars represent correlation coefficients while
their p-values are shown on top. Panel B – Correlations between
changes in abundance of the serum component m/z = 1209 Da in
samples collected during and after RT (C-B; arbitrary units) and
volume irradiated with 34.3 Gy or the maximum AMR intensity.
Figure 3 Dose-volume effects in serum proteome changes.
Panel A – Averaged Dose-Volume Histogram; marked are doses
corresponding to deciles of the area under curve of the histogram.
Panel B - Numbers of serum proteome features correlating with tissue
volume irradiated at a given dose for the AΔB, BΔC, CΔD and AΔD
changes; p = 0.05 was selected as a statistical significance threshold.
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between the maximum AMR intensity and the GTV dose
(ro = 0.30, p = 0.025) or total radiation energy absorbed
by patient’s body (ro = 0.35, p = 0.008). When we looked
for different dose effects the strongest association of themaximum AMR intensity was observed with “intermedi-
ate” doses of radiation (corresponding to 0.8-1 Gy dose
fraction) delivered to substantial volumes of normal tis-
sues (1-2 dm3); Figure 4A. Knowing the correlation be-
tween the AMR and delivered radiation doses, we
searched for its association with changes of serum
proteome features. We found that changes in abun-
dances of several serum components correlated with
the maximum AMR intensity; such correlation was the
most frequent for the AΔB changes (Table 1). Further-
more, a substantial fraction of serum proteome compo-
nents, which changes correlated with the maximum
AMR intensity, also showed significant association with
absorbed radiation doses. This phenomenon could be
exemplified by the peptide ion m/z = 1209 Da, which is
showed in Figure 4B. The data indicated collectively
that radiotherapy-related changes in the serum prote-
ome were affected by radiation doses delivered to large
volumes of normal tissues and reflected biological
mechanisms induced upon irradiation (e.g. acute radi-
ation toxicity). We also searched for potential associ-
ation between RT-induced changes of serum proteome
features and the overall efficacy of the treatment. Two
sub-groups were compared: patients with three-year
recurrence-free survival and patient with local or
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shows the numbers of serum components, which RT-
induced changes in abundance were significantly different
between these two sub-groups. Changes of serum prote-
ome features observed long time after the treatment (i.e.,
the CΔD change) contributed primarily to such differ-
ences. This effect resulted mainly from significant dif-
ference in levels of analyzed components in sample D;
there were 48 components in sample D with signifi-
cantly different levels between compared subgroups. Of
note, none of the serum proteome components that dif-
ferentiated analyzed sub-groups of patients correlated
with either received doses of radiation or maximal in-
tensity of acute radiation toxicity (i.e., the maximal
AMR). Hence, these features of serum proteome pro-
files observed after long time follow-up putatively
reflected the tumor remission or relapse, but not direct
effects of irradiation.
Discussion
We showed here that local irradiation of patients during
the course of head and neck cancer radiotherapy resulted
in gross changes in the low-molecular-weight component
of the serum proteome after the end of RT. The relatively
smaller changes in the serum proteome that were detected
during the first phase of RT could be explained by a lag
period and/or certain dose threshold-requirements of
radiation-induced processes. This observation was coher-
ent with the results of a study performed on a smaller
group of patients treated due to larynx cancer [12]. In the
present study we focused on dose effects and aimed to as-
sess the importance of clinically low and intermediate
doses of radiation delivered to large fractions of normal
tissues. Two previous studies concerning the impact of
local cancer irradiation on the serum proteome, which
revealed the importance of radiation doses, focused on
maximum doses delivered to tumor volume and based
their conclusions on rather heterogenous clinical material
[11,12]. Here, we analyzed homogenous material obtainedTable 2 Numbers of spectral components associated with




(m/z and hypothetical annotation)
AΔB 4 -
BΔC 10 5737, 5755 [SAA1], 5765
AΔC 5 -
CΔD 38 1953, 2192 [HEPC], 2354, 2647, 3579
AΔD 4 -
Numbers of components, for which changes in abundances were different
between subgroups of patients with successful treatment or treatment failure;
p = 0.05 was selected as a significance threshold level. Presented are the
examples of components, for which significance of differences between
sub-groups was p < 0.005.from a relatively large group of patients where no cancer
surgery or chemotherapy was applied. Hence, the hetero-
geneous factors that could interfere with the obtained re-
sults were excluded. We observed that large overall extent
of massive changes induced upon the irradiation appar-
ently impaired ability to detect more refined quantitative
correlations with radiation doses. Nevertheless, association
of specific changes in abundance of serum components
with doses and volumes of irradiated tissue was found. Al-
though correlations identified between specific proteome
features and different parameters reflecting radiation doses
possess moderate statistical power when analyzed separ-
ately, reliable conclusions could be drawn based on the
general patterns of observed association. We noted that
effects of low-to-medium doses delivered to large volumes
of normal tissue were apparently more frequent than ef-
fects of high doses delivered to target volume of tumor,
and concluded that effects of such low-to-medium doses
could be observed at the level of whole body response to
radiotherapy.
We found that massive changes of serum proteome
profiles observed during and soon after the end of radio-
therapy, i.e. “early” effects of irradiation, were somehow
reversed/compensated by “late” changes, observed at
longer times of the follow-up. This apparently reflected
process of return to the initial steady-state level (e.g. accu-
mulation and subsequent healing of radiation damage).
However, “late” radiation-induced changes observed dur-
ing the follow-up were relatively weaker and not always
fully reversed the stronger changes induced during the
treatment. As a consequence, radiation-related changes
could be observed months after the end of radiotherapy
and abundances of several serum components were
significantly different when samples collected more than
one year after the treatment, were compared to samples
collected before the radiotherapy. Similar observation was
made in a group of breast cancer patients where changes
in serum proteome profiles related to the adjuvant radio/
chemotherapy were detected one year after the treatment
[20]. Such results clearly indicated that toxic effects of
anti-cancer therapy are long-lasting and could be detected
as specific features of serum proteome many months after
the treatment. Importantly, this finding indicates the pos-
sible applicability of MS-based analyses of serum prote-
ome profiles in retrospective bio-dosimetry of radiation
exposure. On the other hand, one should note that serum
proteome components involved in a dose/volume-related
“early” radiation response of the organism did not show
significant association with long-term efficacy of the treat-
ment (i.e. tumor eradication vs. re-growth) when a group
of patients with similar prognosis treated with unified
radiotherapy protocol was analyzed.
Model presented in current study is extremely complex
and could be affected by many different processes ongoing
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mulation and subsequent healing of radiation-induced
damage (acute reactions, mucositis, hematological reac-
tions, etc.) would have the major influence on general
therapy-related changes observed at the level of serum
proteome. In fact, we found an association of serum prote-
ome features with the intensity of radiation-induced acute
mucosal reaction, which was in accordance with the ap-
parent correlation between the observed radiation toxicity
and the doses of radiation delivered to normal tissues.
We found the strongest correlation between the muco-
sal reaction and volume irradiated at 30-40 Gy (i.e., at
0.7-1.0 Gy dose fractions). Of note, changes of serum
proteome profiles observed two weeks after the start of
RT, which putatively accompanied escalation of mucosal
reaction, also showed the most frequent correlations
with volume of tissue irradiated at similar “intermedi-
ate” dose fractions (0.7-1.0 Gy). Several peptide ions
registered in the low-molecular-weight fraction of
serum proteome that changed their abundance in sam-
ples from irradiated patients were hypothetically anno-
tated in the proteomic knowledge base EPO-KB [19] as
fragments of proteins related to the inflammation, im-
munity and defense. Among such proteins, there were
acute phase proteins (fibrinogen, haptoglobin, hepcidin,
SAA), complement factors (CO3, CO4A), protease
inhibitors (AACT, ANT3, CYTC, ITIH4), cytokines
(CCL13, CXCL7, OSTP, PLF4, S10AC) and antibacterial
defensins (DEF1, DEF3, DEFB1) (see Additional file 1:
Table S1 and Table S7 for details). These processes are
potentially involved in response to radiation, and several
proteins related to acute phase and inflammation were
previously reported in serum samples collected after
radiotherapy of cancer patients [11]. Hence, we postu-
late that radiation-induced features of the serum prote-
ome, detected in post-treatment samples, correspond to
the direct toxic effects of radiation and/or healing of the
acute reaction.
Due to dosimetrical superiority of IMRT plans this
treatment modality constantly replaces the more “trad-
itional” radiotherapy techniques. Here, we observed that
irradiation of large volumes of normal tissue with doses
of radiation considered as “therapeutically irrelevant”,
which is typical for IMRT, may have some biological ef-
fects. Their potential importance for output of the treat-
ment is not as obvious, because exposure of increased
volume of normal tissues could hypothetically be either
detrimental (e.g. inflammation reactions related to radi-
ation toxicity) or beneficial (e.g. radiation-induced
stimulation of immune reactions). Hence, their clinical
implications need to be carefully considered when
complete data of long-term effects concerning the
IMRT implemented in large cohorts of patients are
available for analyses.Conclusions
This is the first time that the effects of low and intermedi-
ate doses of radiation delivered to a large fraction of nor-
mal tissue have been documented at the level of the serum
proteome. They apparently reflects the general response
of patient’s organism to radiation, indicating potential
biological relevance of therapeutically low doses during
IMRT.
Additional file
Additional file 1: Specific description of registered serum
components.
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